Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9617257
APP PUB NO 20150315210A1
SERIAL NO

14411515

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BETTA PHARMACEUTICALS CO LTD355 XINGZHONG ROAD YUHANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE HANGZHOU ZHEJIANG 311100 HANGZHOU CITY ZHEJIANG PROVINCE 311100

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hu, Shaojing Beijing, CN 32 264
Wang, Fei Beijing, CN 1116 10607
Wang, Yanping Beijing, CN 60 234
Wang, Yinxiang Beijing, CN 19 59
Xu, Zhiguo Beijing, CN 10 91

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 11, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00